Msr-seq laboratory service

Technology
In market
Company

MesoRNA’s MSR-seq™ Laboratory Service provides an end-to-end solution for profiling the small non-coding RNA (sncRNA) system with unprecedented resolution. Conventional small RNA-seq often fails to characterize 90% of nucleic acid activity due to rigid secondary structures, size-selection biases, and complex chemical modifications. Despite the critical role these molecules play in nearly every biological process, a vast portion of the central dogma remains "invisible" to standard technology.

At the core of our methodology is a breakthrough capture hairpin oligonucleotide (CHO) that barcodes and immobilizes RNA molecules on a solid support at the earliest stage of library preparation. This "one-pot" on-bead process eliminates the need for sample precipitation, ensuring the comprehensive capture of the entire sncRNA system—including RNA expression, fragmentation, aminoacylation (charging), and modifications—in a single library.

The MSR-seq™ platform has been extensively validated to ensure superior precision and breadth (Watkins et al. 2022). Technically, the platform maintains high fidelity across a wide dynamic range, with a robust quantitative correlation (r^2 = 0.94) for tRNA isodecoder expression from inputs as low as 10 ng. Accuracy was further confirmed by measuring stoichiometric ligation efficiency across all four 3’ end nucleotides and utilizing poisoned primer extension to verify (m3C) modification signatures. Biologically, the platform has been proven to map multifaceted stress responses, disease signatures, and across multiple starting materials.

Simply ship your total RNA samples to our facility, and our expert team handles the entire pipeline: from library preparation and sequencing to advanced bioinformatics. We deliver publication-ready data and can provide tailored presentations for your stakeholders to help translate results into actionable discovery.


About MesoRNA

MesoRNA specializes in advanced sequencing technologies for small non-coding RNAs, known as mesoRNAs, which range from 30 to 300 nucleotides. The company has developed its proprietary MSR-seq technology to enable comprehensive, multiplexed next-generation sequencing (NGS) library preparation. This platform allows researchers to measure tens of thousands of unique molecules per sample with high base-calling accuracy. Additionally, the company provides a full-service laboratory option for sample processing and is developing a TL-qPCR assay intended to translate biomarker discoveries into diagnostic applications. By addressing the technical challenges historically associated with studying these pervasive but under-researched molecules, MesoRNA aims to complete the understanding of the central dogma of molecular biology.

These tools serve academic laboratories, core facilities, and diagnostic developers who require precise, scalable methods to analyze the biological roles of mesoRNAs. By streamlining the workflow from library preparation to bioinformatics analysis, the company helps users overcome previous limitations in small RNA research. MesoRNA, founded in 2023 and based in Chicago, grew out of over a decade of academic research led by Dr. Tao Pan. The company provides a crucial resource for institutions seeking to investigate the regulatory functions of non-coding RNAs, which constitute a significant majority of human cellular nucleic acids, potentially unlocking new pathways for biological discovery and diagnostic development.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.